Search Results (633)

Introduction: The metabolic complications and poor biocompatibility of conventional glucose-based (GLU) peritoneal dialysis fluid (PDF) have driven the need for improved alternatives. To address this, we developed and evaluated a novel PDF utilizing succinylated gelatin (GEL) as osmotic agent and citrate as buffer, designed to provide effective solute clearance while offering enhanced biocompatibility. Methods: Physicochemical parameters (pH and osmolality) of the novel GEL-PDF were measured. Its performance was assessed in rats with chronic kidney disease. A total of 20 rats were randomized into short-term experiments to evaluate 4 h creatinine clearance and ultrafiltration (UF). A 12-week long-term experiment (n = 35) compared the GEL-PDF against normal saline (NS), GLU, and icodextrin-based (ICO) PDFs, monitoring survival, biochemical parameters, peritoneal membrane histology, and kidney histology. Results: The GEL-PDF demonstrated a neutral pH (7.30) and lower osmolality (317 mOsm/L) compared to GLU-PDF. In the short-term experiment, GEL-PDF achieved effective creatinine clearance by 4 h and provided higher 4 h UF than NS and GLU, comparable to ICO. However, during prolonged dwells (6–16 h), its UF was inferior to ICO. In the long-term experiment, GEL-PDF preserved peritoneal membrane structure, showing the least thickness and collagen deposition. Furthermore, the GEL-PDF demonstrated superior preservation of serum albumin compared to the GLU-PDF. It also exhibited a more favorable lipid profile, as evidenced by significantly lower total cholesterol levels than the ICO group at 12 weeks (p = 0.035), with no adverse effects on electrolytes, liver function, or glucose metabolism. Conclusions: The novel GEL and citrate-based PDF provide effective short-dwell UF and solute removal while exhibiting superior biocompatibility, as evidenced by significant protection against peritoneal membrane injury and favorable metabolic profiles. Although its long-duration UF was lower than that of ICO, it substantially outperformed GLU-PDF. These properties position the GEL-PDF as a promising candidate for short- to medium-dwell exchanges, particularly for daytime use, where it could fill an important clinical gap by providing enhanced UF without the high GLU exposure associated with conventional PDF. Full article

Pyroptosis is a type of programmed cell death (PCD) with pro-inflammatory properties, which is characterized by the swelling with bubbles and the release of LDH and inflammatory cell cytokines. Polyphyllin II (PPII) is the main active ingredient of the Chinese herb Rhizoma Paridis and has been proven to exert high efficacy against a variety of malignant tumors. At present, the anti-tumor research on PPII mainly focuses on apoptosis that is an anti-inflammatory type of PCD, but other potential modes of death cell death and mechanisms of PPII remain to be discovered. Here, we first found that PPII could effectively inhibit the growth of hepatocellular carcinoma (HCC) cells via pyroptosis. After treatment with PPII, the morphology of swelling with bubbles and the formation of pores in the cell membrane in HCC cells were observed, and LDH and cell cytokines (IL-1β, IL-18, IL-6, TNF-α, IFN-β, and IFN-γ) were released. Furthermore, the flow cytometry results showed that PPII could activate oxidative stress by increasing Ca²⁺ influx, thereby promoting the production of ROS to exert anti-tumor effects. RNA sequencing revealed that pyroptosis is closely linked to several signaling pathways, including the MAPK, TNF, Rap1, mTOR, and FoxO pathways, as well as the PD-L1 expression and PD-1 checkpoint pathway. An in vivo study demonstrated that PPII treatment suppressed liver tumor growth in mice by pyroptosis in a dose-dependent manner, and it showed no obvious side effects within a certain range. The Western blot results of tumor tissues revealed that the pyroptosis effect of PPII on liver cancer was associated with the activation of the NLRP3/Caspase1/GSDMD pathway, which upregulates the expression of NLRP3, Cleaved-Caspase 1, GSDMD-N, IL-1β, and IL-18 proteins and downregulates the expression of pro-Caspase 1 and GSDMD proteins. In summary, our findings revealed the pyroptosis effect and mechanism of PPII in HCC cells in vitro and in vivo, suggesting that PPII may be used as a potential pyroptosis inducer for HCC treatment in the future. Full article

The biogas dry reforming reaction offers a promising route for syngas production while simultaneously mitigating greenhouse gas emissions. Membrane reactors have proven to be an excellent option for hydrogen production and separation in a single unit, where conversion and yield can be enhanced over conventional processes. In this study, a Pd/YSZ membrane integrated with a Ru/CeO₂ catalyst was evaluated for biogas reaction under varying operating conditions. The selective removal of hydrogen through the palladium membrane improved reactant conversion and suppressed side reactions such as methanation and the reverse water–gas shift. Experiments were performed at temperatures ranging from 500 to 600 °C, pressures of 1–6 bar, and a gas hourly space velocity (GHSV) of 800 h⁻¹. Maximum conversions of CH₄ (43%) and CO₂ (46.7%) were achieved at 600 °C and 2 bar, while the maximum hydrogen recovery of 78% was reached at 6 bar. The membrane reactor outperformed a conventional reactor, offering up to 10% higher CH₄ conversion and improved hydrogen production and yield. Also, a comparative analysis between Ru/CeO₂ and Ni/Al₂O₃ catalysts revealed that while the Ni-based catalyst provided higher CH₄ conversion, it also promoted methane decomposition reaction and coke formation. In contrast, the Ru/CeO₂ catalyst exhibited excellent resistance to coke formation, attributable to ceria’s redox properties and oxygen storage capacity. The combined system of Ru/CeO₂ catalyst and Pd/YSZ membrane offers an effective and sustainable approach for hydrogen-rich syngas production from biogas, with improved performance and long-term stability. Full article

Developing cost-effective and durable electrocatalysts is essential for advancing anion exchange membrane fuel cells (AEMFCs). This work evaluates Pd-based catalysts supported on β-MnO₂, Vulcan carbon (C), and their physical blend (Pd/MnO₂:Pd/C) as bifunctional electrodes for the oxygen reduction reaction (ORR) and hydrogen oxidation reaction (HOR). The catalysts were synthesized via chemical reduction and characterized by TGA, ICP-OES, TEM, BET, and XRD. Rotating disk electrode studies revealed that the hybrid exhibited superior activity and kinetics, with lower Tafel slopes and higher exchange current densities compared to the individual supports. In AEMFCs, the hybrid reached 128.0 mW cm⁻² as a cathode and 221.7 mW cm⁻² as an anode, outperforming individual components. This enhanced performance arises from the synergistic interaction between Pd nanoparticles and MnO₂, where MnO₂ modulates the catalyst’s microstructure and local reaction environment while the carbon phase ensures efficient electron transport. MnO₂, although inactive for the HOR alone, acted as a structural spacer, enhancing mass transport and stability. Durability tests confirmed that the hybrid electrocatalyst retained over 99% of its initial activity after 3000 cycles. These results highlight the hybrid Pd/MnO₂:Pd/C as a promising, bifunctional, and durable electrocatalyst for AEMFC applications. Full article

Plasmodesmata (PDs) are enriched in sphingolipids and sterols, creating a specialized environment for regulatory proteins like plasmodesmata-localized proteins (PDLPs). How PDLPs regulate PD function in a specific lipid environment remains poorly understood. Here, we provide a unique insight from the interaction network of two different PDLPs together with sphingolipids and propose a concept that PDLPs form homo- or hetero-dimers only in the presence of sphingolipids. Located in the detergent resistance region, PDLP7 demonstrated the ability to influence the sphingolipid composition in PD-enriched fraction, particularly the GIPC content, and finally, modulating the membrane order. The presence of sphingolipids, in turn, affected the oligomeric state of PDLP7 in membranes. The PDLP7 recombinant protein existed as a monomer in vitro, but it formed self-aggregates in yeast and plant cells. We further examined PDLP5, another known phytosphinganine (t18:0)-specific binding PDLP, alongside PDLP7, and confirmed a similar interaction pattern: no direct interaction was observed in vitro, but interactions were noted in vivo. Co-overexpression of the two disrupted their PD localization and induced the upregulation of pathogenesis-related protein 1 (PR1). In summary, we gained insights into the network of PDLPs with lipids and propose that PDLPs were under precise regulation during plant development and stress responses. Full article

The recycling of a planar composite Pd membrane over a porous stainless-steel support modified with a CeO₂ interlayer (Pd/CeO₂/PSS) was investigated using a leaching-based recycling strategy to recover palladium while maintaining the support’s structural integrity. The membrane was prepared by a continuous flowing electroless pore-plating method (cf-ELP-PP) previously developed by our group. A series of experiments was conducted to evaluate the effect of leaching conditions—temperature, acid concentration, and duration—on Pd extraction and support preservation. Nitric acid (HNO₃) was used as the leaching agent, and the condition of 30 vol.% HNO₃ at 35 °C for 24 h was found to enable complete Pd recovery with limited dissolution of metals from the support. The regenerated supports exhibited an Fe-Cr oxide layer and part of the CeO₂ interface, allowing the elimination of cleaning and calcination steps in the membrane reprocessing workflow. A new Pd-CeO₂ interfacial layer was applied, followed by Pd redeposition via cf-ELP-PP. The resulting recycled membrane exhibited a homogeneous and defect-free Pd layer, with hydrogen permeation performance comparable to that of membranes fabricated on fresh supports. These results demonstrate that Pd membranes can be successfully fabricated on recycled 316L stainless-steel substrates, supporting the viability of this approach for material reuse in membrane technology. Full article

Tuberculosis (TB) remains a leading infectious killer, increasingly complicated by multidrug-resistant (MDR) and extensively drug-resistant (XDR) disease; current regimens, although effective, are prolonged, toxic, and often fail to reach intracellular bacilli in heterogeneous lung lesions. This narrative review synthesizes how next-generation antimycobacterial strategies can be translated “from molecule to patient” by coupling potent therapeutics with delivery platforms tailored to the lesion microenvironment. We survey emerging small-molecule classes, including decaprenylphosphoryl-β-D-ribose 2′-epimerase (DprE1) inhibitors, mycobacterial membrane protein large 3 (MmpL3) inhibitors, and respiratory chain blockers, alongside optimized uses of established agents and host-directed therapies (HDTs). These are mapped to inhalable and nanocarrier systems that improve intralesional exposure, macrophage uptake, and targeted release while reducing systemic toxicity. Particular emphasis is placed on pulmonary dry powder inhalers (DPIs) and aerosols for direct lung targeting, stimuli-responsive carriers that trigger release through pH, redox, or enzymatic cues, and long-acting depots or implants that shift daily dosing to monthly or quarterly schedules to enhance adherence, safety, and access. We also outline translational enablers, including model-informed pharmacokinetic/pharmacodynamic (PK/PD) integration, device formulation co-design, manufacturability, regulatory quality frameworks, and patient-centered implementation. Overall, aligning stronger drugs with smart delivery platforms offers a practical pathway to shorter, safer, and more easily completed TB therapy, improving both individual outcomes and public health impact. Full article

Epstein-Barr virus (EBV) infection shows the strongest causative association with multiple sclerosis (MS), but its contribution to disease progression and the mechanisms allowing for viral persistence in the MS brain are still elusive. Studies in post-mortem MS brain tissue indicate an ongoing yet ineffective antiviral immune reaction in advanced stages of the disease. EBV has evolved strategies to evade immune recognition and clearance by the host immune system during both the latency and lytic phase of its life cycle. Recent evidence demonstrates that cells expressing EBV latent membrane protein (LMP) 2A exploit the PD-1/PDL1 inhibitory immune checkpoint to escape immune surveillance and maintain a persistent latent infection in the MS brain. This study investigated whether the virus also utilizes this inhibitory mechanism during other phases of the viral life cycle. By using multiple immunostainings on highly inflamed MS brain tissues containing meningeal tertiary lymphoid structures (TLSs), we analyzed PD-L1 expression on EBV-infected cells expressing EBNA2, five EBV lytic gene products, BZLF1, BHRF1, BMRF1, BALF2, and gp350/220, as well as on follicular dendritic cells within the TLSs. This is the first study describing in secondary progressive MS brain tissue the expression and the cellular and tissue distribution of PD-L1 on EBV-infected cells being in different stages of the viral life cycle, and confirms the meningeal TLSs as immune-permissive habitats favoring the maintenance of an intracerebral EBV reservoir. Full article

Background/Objectives: Advancing information on the key physicochemical properties of biologically active substances enables the development of formulations with reduced dosing, lower toxicity, and minimal adverse effects. This work addresses the knowledge gap concerning the pharmacologically relevant properties of harmaline (HML), with a focus on thermodynamic and kinetic aspects. New data were obtained on the compound’s solubility and distribution coefficients across a wide temperature range. Specifically, solubility was measured in aqueous buffers (pH 2.0 and 7.4), 1-octanol (OctOH), n-hexane (Hex), and isopropyl myristate (IPM), while distribution coefficients were determined in OctOH/pH 7.4, Hex/pH 7.4, and IPM/pH 7.4 systems. Methods: Three membranes—regenerated cellulose (RC), PermeaPad (PP) and polydimethylsiloxane-polycarbonate (PDS)—were used as barriers in permeability studies using a Franz diffusion cell. Results: At 310.15 K, the molar solubility of HML in the solvents decreased in the following order: OctOH > pH 2.0 > pH 7.4 > IPM > Hex. The distribution coefficient of HML showed a strong dependence on the nature of the organic phase, correlating with its solubility in the respective solvents. The OctOH/pH 7.4 distribution coefficient ranged from 0.973 at 293.15 K to 1.345 at 313.15 K, falling within the optimal range for potential drug bioavailability. The transfer of HML into OctOH (from either pH 7.4 or hexane) is thermodynamically spontaneous, whereas its transfer into Hex is unfavorable. Conclusions: Based on its permeability across the PP barrier, HML was classified as highly permeable. The distribution and permeation profiles of HML showed similar trends over 5 h in both the OctOH/pH 7.4–PP and IPM/pH 7.4–PDS systems. These systems were therefore proposed as suitable models for studying HML transport in vitro. Full article

Contaminated water detoxification remains difficult due to the presence of persistent halo-organic contaminants, such as perfluorooctanoic acid (PFOA) and chlorophenols, which are chemically stable and resist conventional purification methods. Functionalized membrane-based separation and decontamination have garnered immense attention in recent years. Commercially available microfiltration membrane (PVDF) and polymeric non-woven fiber filters (glass and composite) are functionalized with poly(methacrylic acid) (PMAA) that shows outstanding pH-responsive performance and tunable water permeability under ambient conditions perfect for environmental applications. Polymer loading based on weight gain measurements on PMAA–microglass composite fibers (137%) and microglass fibers (116%) confirmed their extent of functionalization, which was significantly greater than that of PVDF (25%) due to its widely effective pore diameter. Presence of chemically active hydrogel within PVDF matrix was validated by FTIR (hydroxyl/carbonyl) stretch peak, substantial decrease in contact angle (68.8° ± 0.5° to 30.8° ± 1.9°), and decrease in pure water flux from 509 to 148 LMH/bar. Nanoparticles are generated both in solution and within PVDF using simple redox reactions. This strategy is extended to PVDF-PMAA membranes, which are loaded with Fe/Pd nanoparticles for catalytic conversion of 4-chlorophenol and PFOA, forming Fe/Pd-PVDF-PMAA systems. A total of 0.25 mg/L Fe/Pd nanoparticles synthesized in solution displayed alloy-type structures and demonstrated a strong catalytic performance, achieving complete hydrogenation of 4-chlorophenol to phenol and 67% hydrogenation of PFOA to its reduced form at 22–23 °C with ultrapure hydrogen gas supply at pH 5.7. These results underscore the potential of hybrid polymer–nanoparticle systems as a novel remediation strategy, integrating tunable separation with catalytic degradation to overcome the limitations of conventional water treatment methods. Full article

Evidence increasingly indicates that synaptic vesicle dysfunction emerges early in Parkinson’s disease (PD), preceding overt dopaminergic neuron loss rather than arising solely as a downstream consequence of neurodegeneration. α-Synuclein (αSyn), a presynaptic protein that regulates vesicle clustering, trafficking, and neurotransmitter release under physiological conditions, exhibits dose-, conformation-, and context-dependent actions that distinguish its normal regulatory roles from pathological effects observed in disease models. This narrative review synthesizes findings from a structured search of PubMed and Scopus, with emphasis on α-syn-knockout (αSynKO) and BAC transgenic (αSynBAC) mouse models, which do not recapitulate the full human PD trajectory but provide complementary insights into αSyn physiological function and dosage-sensitive vulnerability. Priority was given to studies integrating ultrastructural approaches—such as cryo-electron tomography, high-pressure freezing/freeze-substitution TEM, and super-resolution microscopy—with proteomic and lipidomic analyses. Across these methodologies, several convergent presynaptic alterations are consistently observed. In vivo and ex vivo studies associate αSyn perturbation with impaired vesicle acidification, consistent with altered expression or composition of vacuolar-type H⁺-ATPase subunits. Lipidomic analyses reveal age- and genotype-dependent remodeling of vesicle membrane lipids, particularly curvature- and charge-sensitive phospholipids, which may destabilize αSyn–membrane interactions. Complementary biochemical and cell-based studies support disruption of SNARE complex assembly and nanoscale release-site organization, while ultrastructural analyses demonstrate reduced vesicle docking, altered active zone geometry, and vesicle pool disorganization, collectively indicating compromised presynaptic efficiency. These findings support a synapse-centered framework in which presynaptic dysfunction represents an early and mechanistically relevant feature of PD. Rather than advocating αSyn elimination, emerging therapeutic concepts emphasize preservation of physiological vesicle function—through modulation of vesicle acidification, SNARE interactions, or membrane lipid homeostasis. Although such strategies remain exploratory, they identify the presynaptic terminal as a potential window for early intervention aimed at maintaining synaptic resilience and delaying functional decline in PD. Full article

Background/Objectives: The accumulation of specific amyloid proteins and peptides in the human brain is a hallmark of neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Beyond the central nervous system, circulating peripheral blood cells are also exposed to these pathological proteins, which may contribute to the systemic disease manifestation. Human platelets (PLTs) were used as an in vitro model to investigate the impacts of amyloid Aβ1-42 peptide oligomers (Aβ42) and on-pathway α-synuclein (α-syn), two key amyloids implicated in AD and PD, on platelet biophysical properties. Methods: Using atomic force microscopy, imaging and force–distance modes, we analyzed changes in surface nanostructure, morphometric and nanomechanical signatures of PLTs, derived from healthy donors, following exposure to increasing concentrations of Aβ42 and α-syn. Results: Our findings show that platelet activation progresses with increasing amyloid concentration, characterized by cytoskeletal remodeling (filopodia-to-pseudopodia and lamellipodia transformation). While Aβ42 causes progressive decrease in the platelet membrane roughness, α-syn exhibits a biphasic effect—initial smoothing followed by a pronounced increase in the roughness at high concentrations. Both amyloids induce substantial increase in membrane stiffness (Young’s modulus). Conclusions: The changes in PLTs’ biophysical properties closely resemble the previously observed modification in PLTs derived from AD and PD patients, suggesting that amyloid proteins’ interactions with PLTs may contribute to their dysfunction. Our results underscore the potential of platelets as peripheral indicators of neurodegeneration and point to their role in the systemic pathology of amyloid-associated diseases. Full article

Anion exchange membrane fuel cells (AEMFCs) are the most feasible choice of catalyst due to their high efficiency and scale of commercialization. However, the challenge posed by the sluggish kinetics of AEMFCs can only be countered by an effective electrocatalyst that enhances the reaction kinetics and, thereby, the fuel cell performance. The Pd-Co/C cathode catalyst is a promising choice of electrocatalyst, with the phenomenon of alloying playing a key role at appropriate temperatures and residence time distributions of annealing due to the influence of the lattice parameter, electrochemically active surface area (ECSA), and particle size. After completing the synthesis of 20 wt.% Pd-Co/C, the catalyst was treated under various annealing and loading conditions. This was subsequently followed by a series of physicochemical and electrochemical characterizations that verified the successful synthesis of the catalyst material, paving a path to optimizing the annealing temperature, annealing residence time, and catalyst loading. Further, proceeding with the fuel cell test runs with multiple profiles of the above parameters resulted in the optimization of the annealing temperature, residence time of annealing, and catalyst loading, and it was subsequently concluded that the best performance of the fuel cell was achieved when the Pd-Co/C catalyst was annealed at 500 °C for a duration of 1 h and loaded at 0.25 mg/cm², which resulted in an impeccable power density of 724 mW/cm². Full article

Cancer cell plasticity drives metastasis and therapy resistance through dynamic transitions between epithelial, mesenchymal, and neural crest stem-like (NCSC) states; however, a unifying mechanism that stabilizes these transitions remains undefined. To address this gap, we introduce a N-cadherin (CDH2)-centered redox–adhesion–exosome (RAX) hub that links oxidative signaling, adhesion dynamics, and exosome-mediated immune communication into a closed-loop framework. Within this network, reactive oxygen species (ROS) pulses license epithelial–mesenchymal transition (EMT), AXL–FAK/Src signaling consolidates mesenchymal adhesion, and selective exosomal cargoes—including miR-21, miR-200, miR-210, and PD-L1—propagate plasticity and immune evasion. Lipid peroxidation acts as a central checkpoint connecting ROS metabolism to PUFA membrane remodeling and ferroptosis vulnerability, buffered by NRF2–GPX4 and FSP1/DHODH axes, thereby converting transient oxidative pulses into persistent malignant states. Mechanistically, the RAX hub synthesizes findings from EMT/CSC biology, ferroptosis defenses, and exosome research into a self-reinforcing system that sustains tumor heterogeneity and stress resilience. Evidence from single-cell and spatial transcriptomics, intravital ROS imaging, and exosome cargo-selector studies supports the feasibility of this model. We further outline validation strategies employing HyPer–EMT–CDH2 tri-reporters, CRISPR perturbation of YBX1/ALIX cargo selectors, and spatial multi-omics in EMT-high tumors. Clinically, tumors enriched in EMT/NCSC programs—such as melanoma, neuroblastoma, small-cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer (TNBC)—represent RAX-dependent contexts. These insights highlight biomarker-guided opportunities to target adhesion switches, ferroptosis defenses, and exosome biogenesis through lipid peroxidation-centered strategies using liquid-biopsy panels (exosomal CDH2, miR-200, miR-210) combined with organoid and xenograft models. By linking lipid peroxidation to ferroptosis defense and oxidative stress adaptation, the RAX hub aligns with the thematic focus of lipid metabolism and redox control in cancer progression. Collectively, the RAX framework may provide a conceptual basis for precision oncology by reframing metastasis and therapy resistance as emergent network properties. Full article

Immune checkpoint inhibitors (ICIs), particularly PD-1/PD-L1 antibodies, have significantly improved outcomes in a variety of solid tumors, including urothelial carcinoma. However, their use is frequently associated with immune-related adverse events (irAEs) which frequently affect the skin and mucous membranes. Among these, plasma-cell-rich infiltrates are exceptionally rare. Circumorificial plasmacytosis (COP) is a rare, predominantly reactive condition typically involving mucosal transition zones, with histologic features characterized by dense, polyclonal plasma cell infiltrates and a benign clinical course. Only two case reports have described COP in association with ICI therapy and, to date, transformation or overlap with lymphoproliferative disorders such as marginal zone lymphoma has not been documented. We report the case of an 86-year-old male with urothelial carcinoma who developed a progressive, ulcerated, bleeding lesion of the lower lip during adjuvant nivolumab therapy. Histologic examination revealed a dense subepithelial infiltrate of mature plasma cells and lymphocytes. Direct and indirect immunofluorescence studies were negative, excluding autoimmune blistering disorders. Immunohistochemistry showed a predominance of CD138-positive plasma cells with a moderate kappa light-chain shift, CD19 expression, and absence of CD56, Cyclin-D1, and CD117, arguing against a plasma cell neoplasm. Molecular analysis via multiplex PCR revealed a clonal B-cell population with distinct IgH rearrangements, and some EBV-positive cells were also identified by EBER in situ hybridization. The histopathologic and molecular findings suggested a marginal zone lymphoma-like, plasmacytic proliferation arising in the setting of COP. This case illustrates a rare and diagnostically challenging constellation at the intersection of reactive and clonal B-cell proliferations in the context of ICI therapy. Although the lesion demonstrated features of clonality, the overall low B-cell content, indolent clinical course, and lack of systemic involvement support a reactive, immunodeficiency-associated lymphoproliferation rather than overt lymphoma. This case expands the known spectrum of mucocutaneous irAEs and highlights the need for careful clinicopathologic correlation, including immunophenotyping and molecular diagnostics. Awareness of such rare presentations is essential to avoid overdiagnosis and unnecessary systemic treatment in patients with otherwise indolent lesions. Full article